• 中国核心期刊(遴选)数据库收录期刊
  • 中文科技期刊数据库收录期刊
  • 中国期刊全文数据库收录期刊
  • 中国学术期刊综合评价数据库统计源期刊等

中国药物评价 ›› 2023, Vol. 40 ›› Issue (4): 338-343.

• 药品评价 • 上一篇    下一篇

基于GRADE系统的IL-17抑制剂治疗银屑病的系统评价再评价

令娟1,2, 郝江华2, 卢苇1, 何宝峰1, 罗旭飞3, 谢卓霖4, 张定华4, 张青叶4, 罗向霞4*   

  1. 1.甘肃中医药大学, 甘肃 兰州 730000;
    2.甘肃省人民医院, 甘肃 兰州 730000;
    3.兰州大学循证医学中心,甘肃 兰州 730000;
    4.甘肃省中医院, 甘肃 兰州 730000
  • 收稿日期:2023-02-13 修回日期:2023-06-05 出版日期:2023-08-28 发布日期:2023-08-28
  • 基金资助:
    甘肃省名中医张定华传承工作室建设项目,“甘卫中医函[2022]50号”

Overviews of Systematic Reviews of Psoriasis with IL-17 Inhibitors Based on GRADE System

  1. 1.Gansu University of Traditional Chinese Medicine, Gansu Lanzhou 730000, China;
    2.Gansu Provincial People′s Hospital, Gansu Lanzhou 730000, China;
    3.Evidence based Medicine Center of Lanzhou University,Gansu Lanzhou 730000, China;
    4.Gansu Provincial Hospital of Traditional Chinese Medicine, Gansu Lanzhou 730000, China
  • Received:2023-02-13 Revised:2023-06-05 Online:2023-08-28 Published:2023-08-28

摘要: 目的:对白介素17(IL-17)抑制剂治疗银屑病的系统评价/Meta分析进行系统评价再评价,为临床医师用药及决策者提供本领域相关的循证证据。方法:检索中英文数据库,包括Cochrane图书馆、PubMed、Embase、中国生物医学文献数据库、万方数据库和中国知网等,获取IL-17抑制剂治疗银屑病的系统评价/Mate分析研究,检索时间均为各数据库建库始至2022年11月。根据本研究设定的纳入排除标准进行文献筛选,对纳入文献进行资料提取后,采用证据质量分级和推荐强度(GRADE)系统对纳入研究的证据质量等级进行评价,并对结局指标的证据进行整合总结。结果:最终纳入14篇文献,结局指标共计44个,GRADE证据质量等级为中高质量,5个(11%)结局指标是低质量,有24个(55%)结局指标是中等质量,有15个(34%)结局指标是高质量。结局指标疗效的证据总结显示,IL-17抑制剂治疗银屑病在增加PASI90、PASI100及PASI175患者比例方面,与安慰剂相比,IL-17抑制剂组患者的银屑病皮损面积和严重程度指数(PASI)评分较基线下降≥90%、100%及175%的患者比例均显著高于安慰剂组;与其他药物(依那西普)相比,布罗达单抗210mg在增加PASI100时效果类似;与乌司奴单抗相比,在增加PASI90及PASI100时,苏金单抗及布罗达单抗的疗效均优于乌司奴单抗。结论:IL-17抑制剂治疗银屑病的系统评价/Meta分析研究的证据质量为中高质量水平,并且基于其证据质量及结局指标整合结果表明,IL-17抑制剂在治疗银屑病时具有较好的临床效果。

关键词: font-size:medium, ">IL-17抑制剂;银屑病;系统评价再评价

Abstract: Objective: To overvierw the efficacy of interleukin-17 inhibitor in the treatment of psoriasis and provide evidence-based reference for clinical use of this drug in the treatment of psoriasis. Methods: The Chinese and English databases were searched to collect the systematic reviews/Meta analysis of the treatment of psoriasis with interleukin 17 inhibitors.The quality of the evidence included in the study was evaluated using the evidence quality grading and recommendation strength (GRADE) system, and the outcome indicators of efficacy and safety were summarized. Results: Totally 14 studies were included. GRADE evidence quality grade was medium and high quality. Evidence summary shows that the evidence of increasing the proportion of patients with PASI90, PASI100 and PASI175 in the treatment of psoriasis with IL-17 inhibitors is summarized. Compared with other drugs (etanercept), Brodamab 210mg has similar effect in increasing PASI100. Compared with ulinuzumab, when increasing PASI90 and PASI100, the efficacy of Suginuzumab and Brodaumab is better than that of ulinuzumab. Conclusion: The evidence quality of systematic reviews/Meta analysis of IL-17 inhibitors in the treatment of psoriasis is medium and high quality, and these drugs have good clinical efficacy in the treatment of psoriasis.

Key words: font-size:medium, ">IL-17 inhibitor; Psoriasis; Overviews of Systematic Reviews

中图分类号: